Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 7/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 1.00 |
| ▸ | KMO | O15229 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.62 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.62 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.59 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.59 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788154 | 1.00 | MKNK1 (1.00) | MKNK1MKNK2KMOALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL5548436 | 0.98 | MKNK1 (0.96) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL12348482 | 0.87 | MKNK1 (0.77) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL28349168 | 0.87 | MKNK1 (0.77) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL27605181 | 0.86 | MKNK1 (0.76) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL10168717 | 0.84 | MKNK1 (0.70) | MKNK1MKNK2KMOALDH1A1IP6K1 | |
| SCHEMBL17089048 | 0.83 | KMO (0.77) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL606654 | 0.83 | MKNK1 (1.00) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL206263 | 0.83 | MKNK1 (0.71) | MKNK1MKNK2KMOALDH1A1GAA | |
| SCHEMBL30855339 | 0.83 | MKNK1 (1.00) | MKNK1MKNK2ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717465-B1 | COMPOUNDS | STEP PHARMA S A S (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | UNIV ANTWERPEN (BE) | 2025-11-20 | — | — | US | disclosed |
| US-20250263407-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-08-21 | — | — | US | disclosed |
| EP-4603488-A1 | NOVEL INDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-08-20 | — | — | EP | disclosed |
| EP-4594294-A1 | DOPAMINE D3/D2 RECEPTOR PARTIAL AGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | BNH RESEARCH CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-12319680-B2 | Compounds | STEP PHARMA S.A.S. (FR) | 2025-06-03 | — | — | US | disclosed |
| EP-4501911-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | BNH Research Co., Ltd. (KR) | 2025-02-05 | — | — | EP | disclosed |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | INITIAL THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024226875-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS | INITIAL THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2001014358-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL) DIHYDROBENZOFURANS AND BENOZOPYRANS | AVENTIS PHARMACEUTICALS INC. (DE) | 2001-03-01 | — | — | WO | disclosed |
| CN-1278793-A | Sulfonyl derivatives | DAIICHI SEIYAKU CO (JP) | 2001-01-03 | — | — | CN | disclosed |
| EP-1031563-A1 | SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-08-30 | — | — | EP | disclosed |
| WO-2000039087-A2 | SUBSTITUTED (AMINOIMINOMETHYL OR AMINOMETHYL)BENZOHETEROARYL COMPOUNDS AS FACTOR XA INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| EP-0986551-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Pharmaceutical Company Limited (JP) | 2000-03-22 | — | — | EP | disclosed |
| WO-2000006085-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
| CN-1236358-A | Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides | RHONE POULENC RORER PHARMA (US) | 1999-11-24 | — | — | CN | disclosed |
| EP-0931060-A1 | SUBSTITUTED N- (AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-28 | — | — | EP | disclosed |
| WO-1999000356-A1 | SUBSTITUTED N-[(AMINOIMINOMETHYL OR AMINOMETHYL)PHENYL]PROPYL AMIDES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1998054164-A1 | SULFONAMIDE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319680-B2 | Compounds | UGT1A1, CYP1A1, CYP1B1 | MKNK1 2780/4885MKNK2 2655/4885KMO 2606/4885 |
| US-20250263407-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | MKNK1 2655/4885MKNK2 2513/4885KMO 2620/4885 |
| US-20250213560-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS HAVING PHENYL GROUP AND USES THEREOF | PNMT, BDNF, NLN | MKNK1 552/4885MKNK2 443/4885KMO 333/4885 |
| US-20240400555-A1 | Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors | MYCBP, MYC, MYCBP2 | MKNK1 1080/4885MKNK2 1048/4885KMO 3956/4885 |
| US-20250353833-A1 | DPP9 BINDING COMPOUNDS | DPP9, DPP7, DPP3 | MKNK1 1403/4885MKNK2 1953/4885KMO 2636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.